Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Emergent BioSolutions

< Previous 1 2 Next >
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.